Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Mar

Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval

On March 17, 2025, US time, the world’s first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hot...

Read article >

Mar

Another milestone! Sungen Biomedical presented anti-tumor bispecific antibody SGT003 at the JP Morgan Healthcare Annual Conference.

At the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), which attracted the attention of global medical industry, Sungen Biomedical's innovative bi-specific antibody SGT003 was unve...

Read article >

Mar

Riding the wave, The world's first acute myocardial infarction antibody SGC001 of Sungen Biomedical was presented at U.S. J.P. Morgan Conference

On January 12th, the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), an influential investment seminar, took place in San Francisco. Sungen Biomedical made a notable presentation featu...

Read article >